Peter M Monti Selected Research

Peter M Monti Research Topics

10	Alcoholism (Alcohol Abuse) 08/2023 - 03/2004
10	Substance-Related Disorders (Drug Abuse) 10/2017 - 05/2004
3	HIV Infections (HIV Infection) 04/2021 - 01/2016
3	Substance Withdrawal Syndrome (Withdrawal Symptoms) 03/2009 - 02/2007
3	Alcohol-Related Disorders 01/2008 - 07/2004
2	Tobacco Use Disorder (Nicotine Dependence) 12/2021 - 08/2013
2	Marijuana Use 02/2008 - 06/2007
1	Infections 11/2021
1	COVID-19 11/2021
1	Hypertension (High Blood Pressure) 04/2021
1	Inflammation (Inflammations) 04/2021
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 06/2020
1	Coinfection 01/2019
1	Depressive Disorder (Melancholia) 10/2017
1	Cognitive Dysfunction 01/2016
1	Genetic Risk Score 01/2012
1	Confusion (Bewilderment) 02/2011
1	Psychotic Disorders (Schizoaffective Disorder) 06/2008
1	Cocaine-Related Disorders (Cocaine Addiction) 09/2007
1	Pain (Aches) 05/2004

6	SmokeIBA 01/2017 - 05/2005
5	Nicotine FDA Link 10/2017 - 05/2005
5	Cocaine (Cocaine HCl)IBA 09/2007 - 05/2004
3	Topiramate (Topamax)FDA LinkGeneric 01/2016 - 03/2008
3	Naltrexone (ReVia)FDA LinkGeneric 02/2013 - 02/2007
2	Opioid Receptors (Opioid Receptor)IBA 01/2013 - 01/2008
1	CotinineIBA 12/2021
1	Opioid Analgesics (Opioids)IBA 11/2021
1	CarcinogensIBA 04/2021
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Lipopolysaccharide ReceptorsIBA 01/2019
1	Varenicline (Chantix)FDA Link 10/2017
1	Indicators and Reagents (Reagents)IBA 08/2013
1	Bupropion (Wellbutrin)FDA LinkGeneric 01/2012
1	Dronabinol (THC)FDA LinkGeneric 02/2011
1	Anticonvulsants (Antiepileptic Drugs)IBA 04/2009
1	Olanzapine (Zyprexa)FDA Link 06/2008
1	Antipsychotic Agents (Antipsychotics)IBA 06/2008
1	24,25-oxidolanosterol (OLAN)IBA 06/2008
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2008

4	Condoms (Condom) 04/2021 - 02/2008
3	Tobacco Use Cessation Devices 10/2017 - 03/2004
2	Drug Therapy (Chemotherapy) 01/2016 - 07/2008
2	Therapeutics 04/2006 - 03/2004
1	Continuity of Patient Care 08/2023
1	Art Therapy 01/2016